HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Glucokinase regulatory protein genetic variant interacts with omega-3 PUFA to influence insulin resistance and inflammation in metabolic syndrome.

AbstractUNLABELLED:
Glucokinase Regulatory Protein (GCKR) plays a central role regulating both hepatic triglyceride and glucose metabolism. Fatty acids are key metabolic regulators, which interact with genetic factors and influence glucose metabolism and other metabolic traits. Omega-3 polyunsaturated fatty acids (n-3 PUFA) have been of considerable interest, due to their potential to reduce metabolic syndrome (MetS) risk.
OBJECTIVE:
To examine whether genetic variability at the GCKR gene locus was associated with the degree of insulin resistance, plasma concentrations of C-reactive protein (CRP) and n-3 PUFA in MetS subjects.
DESIGN:
Homeostasis model assessment of insulin resistance (HOMA-IR), HOMA-B, plasma concentrations of C-peptide, CRP, fatty acid composition and the GCKR rs1260326-P446L polymorphism, were determined in a cross-sectional analysis of 379 subjects with MetS participating in the LIPGENE dietary cohort.
RESULTS:
Among subjects with n-3 PUFA levels below the population median, carriers of the common C/C genotype had higher plasma concentrations of fasting insulin (P = 0.019), C-peptide (P = 0.004), HOMA-IR (P = 0.008) and CRP (P = 0.032) as compared with subjects carrying the minor T-allele (Leu446). In contrast, homozygous C/C carriers with n-3 PUFA levels above the median showed lower plasma concentrations of fasting insulin, peptide C, HOMA-IR and CRP, as compared with individuals with the T-allele.
CONCLUSIONS:
We have demonstrated a significant interaction between the GCKR rs1260326-P446L polymorphism and plasma n-3 PUFA levels modulating insulin resistance and inflammatory markers in MetS subjects. Further studies are needed to confirm this gene-diet interaction in the general population and whether targeted dietary recommendations can prevent MetS in genetically susceptible individuals.
TRIAL REGISTRATION:
ClinicalTrials.gov NCT00429195.
AuthorsPablo Perez-Martinez, Javier Delgado-Lista, Antonio Garcia-Rios, Jolene Mc Monagle, Hanne L Gulseth, Jose M Ordovas, Danielle I Shaw, Brita Karlström, Beata Kiec-Wilk, Ellen E Blaak, Olfa Helal, Małgorzata Malczewska-Malec, Catherine Defoort, Ulf Risérus, Wim H M Saris, Julie A Lovegrove, Christian A Drevon, Helen M Roche, Jose Lopez-Miranda
JournalPloS one (PLoS One) Vol. 6 Issue 6 Pg. e20555 ( 2011) ISSN: 1932-6203 [Electronic] United States
PMID21674002 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Blood Glucose
  • Carrier Proteins
  • Fatty Acids, Monounsaturated
  • Fatty Acids, Omega-3
  • Fatty Acids, Omega-6
  • glucokinase regulatory protein
  • C-Reactive Protein
Topics
  • Adult
  • Aged
  • Blood Glucose (metabolism)
  • C-Reactive Protein (metabolism)
  • Carrier Proteins (genetics, metabolism)
  • Fatty Acids, Monounsaturated (metabolism)
  • Fatty Acids, Omega-3 (metabolism)
  • Fatty Acids, Omega-6 (metabolism)
  • Female
  • Genetic Loci (genetics)
  • Homeostasis (genetics)
  • Humans
  • Inflammation (complications, genetics, metabolism)
  • Insulin Resistance (genetics)
  • Male
  • Metabolic Syndrome (complications, genetics, metabolism)
  • Middle Aged
  • Polymorphism, Genetic
  • Protein Binding

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: